ticker nerd logo
Hologic Inc

Hologic Inc Stock Forecast & Price Prediction

Live Hologic Inc Stock (HOLX) Price
$74.58

7

Ratings

  • Buy 3
  • Hold 4
  • Sell 0
Disclaimer : The analyst ratings and price forecast data are provided by Tradefeeds. The data is sourced from Wall Street analysts and other experienced experts. The figures presented are solely a forecast and not a guarantee of future price performance. The information presented is not a recommendation to buy or sell the stock.

Stock Price

$74.58

P/E Ratio

P/E Ratio not available for HOLX

Volume Traded Today

$1.4M

Dividend

Dividends not available for HOLX

52 Week High/low

87.88/64.02

Hologic Inc Market Cap

$17.32B

🛑 Alert: These ten stocks could have higher potential than $HOLX 🛑

Before you buy HOLX you’ll want to see this list of ten stocks that have huge potential. Want to see if HOLX made the cut? Enter your email below

HOLX Summary

From what 7 stock analysts predict, the share price for Hologic Inc (HOLX) might increase by 11.68% in the next year. This is based on a 12-month average estimation for HOLX. Price targets go from $76.00 to $90.00. The majority of stock analysts believe HOLX is a buy. Please note analyst price targets are not guaranteed and could be missed completely.

HOLX Analyst Ratings

Hologic Inc has a total of 7 Wall St Analyst ratings. There are 3 buy ratings, 4 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that Hologic Inc will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.

HOLX stock forecast by analyst

Analyst/Firm

Rating

Price Target

Change

Date

amit hazan
Goldman Sachs

Sell

$15.0

initiatedcoverage

Nov 11, 2013
todd thomas
KeyBanc

Sell

None

downgraded

May 5, 2009

HOLX Company Information

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth. The company also offers breast cancer care solutions in the areas of radiology, breast surgery, pathology, and treatment, such as 3D digital mammography systems, image analytics software, reading workstations, minimally invasive breast biopsy guidance systems, breast biopsy site markers, localization, specimen radiology, and connectivity solutions; and breast conserving surgery products. In addition, it provides MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids and polyps in the uterus; NovaSure Endometrial Ablation System to treat abnormal uterine bleeding; Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures; Acessa ProVu system to treat various fibroids; and CoolSeal portfolio, such as bipolar vessel sealing devices. Further, the company offers Horizon DXA, a dual energy X-ray system; and Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. It sells its products through direct sales, service forces, independent distributors, and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.

HOLX
Hologic Inc (HOLX)

When did it IPO

1990

Staff Count

6,990

Country

United States

Sector/Industry

Healthcare/Medical Instruments & Supplies

CEO

Mr. Stephen P. MacMillan

Market Cap

$17.32B

Hologic Inc(HOLX) Financial Data

In 2023, HOLX generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that HOLX's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.

Revenue From 2019

N/A

Revenue From 2020

N/A

0.00 %
From Previous Year

Revenue From 2021

N/A

0.00 %
From Previous Year

Revenue From 2022

N/A

0.00 %
From Previous Year
  • Revenue TTM $3.97B
  • Operating Margin TTM 0.22%
  • Gross profit TTM $2.07B
  • Return on assets TTM 0.06%
  • Return on equity TTM 0.11%
  • Profit margin 0.12977%
  • Book value 19.84%
  • Market capitalisation $17.32B
  • Revenue for 2020 N/A
  • Revenue for 2021 N/A
  • Revenue for 2022 N/A
  • EPS this year 2.11
  • EPS next year N/A
... ...

Similar Stocks to Hologic Inc HOLX

🛑 Alert: These ten stocks could have higher potential than $HOLX 🛑

Before you buy HOLX you’ll want to see this list of ten stocks that have huge potential. Want to see if HOLX made the cut? Enter your email below

...

HOLX Frequently asked questions

The highest forecasted price for HOLX is $90.00 from dan leonard at Credit Suisse.

The lowest forecasted price for HOLX is $76.00 from conor mcnamara from RBC Capital

The HOLX analyst ratings consensus are 3 buy ratings, 4 hold ratings, and 0 sell ratings.